• Users Online: 133
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2016  |  Volume : 5  |  Issue : 2  |  Page : 178-182

Assessment of interleukin-10 level and Janus kinase 2 V617F mutation incidence in patients with primary myelofibrosis

Laboratory Department, Cytogenetic Unit, National Center of Hematology, Al-Mustansiriya University, Baghdad, Iraq

Correspondence Address:
Shahla'a Fadhil Sabir
Cytogenetic Unit, National Center of Hematology, Al-Mustansiriya University, Baghdad
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2072-8069.198126

Rights and Permissions

Background: Myelofibrosis (MF) is largely documented by an abnormal cytokine expression, which in turn could contribute to bone marrow fibrosis, angiogenesis, and constitutional symptoms. To gain additional pathogenetic insight regarding cytokine phenotype correlations in MF, this study estimated the level of interleukin-10 (IL-10) abnormality and Janus kinase (JAK2 V617F) mutation in primary MF. Objective: The objective of this study was to assess serum IL-10 level and it's relation with the presence of JAK2 V617F mutation in patients with MF. Materials and Methods: JAK2 V617F mutation detection was performed in 32 patients with MF using amplification refractory mutation screening-polymerase chain reaction. IL-10 level was estimated in 36 patients with MF using enzyme-linked immunosorbent assay technique compared to 27 healthy controls who were enrolled for comparison. Results: The study showed higher significant (P ≤ 0.002) increase of IL-10 in patients with MF with cutoff value ≥8.9510 pg/ml and area under the curve value of 0.749 (P < 0.001) and also in patients with serum level of IL-10 more than 13.6 pg/ml characterized with significant lower white blood cell count, nonsignificant difference with lower hemoglobin level, normal platelet count, and smaller size splenomegaly. About 59% of the studied primary MF (PMF) patients had JAK2 positive, 63% of them were male. There was no significant correlation between IL-10 and JAK2. Conclusion: JAK2 mutation and IL-10 as anti-inflammatory cytokines may play a role in the pathogenesis and hematological presentation of patients with PMF. High IL-10 level may predict good prognosis in patients with PMF.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded82    
    Comments [Add]    

Recommend this journal